Hospital

Adding anthracyclines to chemotherapy may improve survival in high-risk breast cancer patients.

Advancements in prevention address cancer risk in high-risk patients and BRCA mutation carriers.

Combining CDK4/6 and PDL-1 inhibitors enhances treatment responses in patients with hormone receptor positive and triple-negative breast cancer.

Despite the overall decline in medication non-adherence, adult patients with asthma are continuing to report taking less or skipping doses and refilling prescriptions later to save money.

Pharmacists can make a significant impact by providing medication management, promoting nonpharmacologic approaches, supporting patients through life transitions.

Daily operational tasks and quality assurance measures in pharmacy compounding ensures patient safety and maintains compliance.

The pumps can now be used to treat pediatric patients who have symptomatic acute decompensated heart failure and cardiogenic shock.

The novel camizestrant-ribociclib combination demonstrated encouraging data in advanced, pre-treated ER+/HER2- breast cancer.

Breast cancer prevention vaccines could have significant positive societal impact by reducing cancer diagnoses.

Novel therapies and personalized treatment plans are improving outcomes for patients with ER-positive breast cancer.

Trastuzumab deruxtecan and trastuzumab emtansine address key challenges such as recurrence and metastases in HER2+ early breast cancer treatment.

Pharmacists can help drive the successful adoption of biosimilars by developing educational programs to address provider and patient concerns.

The combination of elacestrant and abemaciclib showed promising 8.7-month progression-free survival in ER+, HER2- advanced breast cancer, including in patients with ESR1 mutations.

The assessment of tumor-infiltrating lymphocytes can provide valuable insights to guide personalized treatment decisions for breast cancer patients.

At the 2024 San Antonio Breast Cancer Symposium, experts discussed the development, clinical impact, and challenges of antibody-drug conjugates (ADCs).

Both risk-reducing mastectomy and salpingo-oophorectomy were associated with significant improvements among young BRCA carriers with breast cancer.

Assessing pre-treatment TIL levels in young breast cancer patients could help predict response to neoadjuvant chemotherapy.

Experts highlight the importance of dosing and regimen optimization in breast cancer to improve treatment tolerability, reduce toxicities, and improve quality of life for patients.

Rural patients face significant barriers to health care access and affordability that contribute to poor hypertension management.

Komal Jhaveri MD, FACP, shares that the combination of imlunestrant plus abemaciclib further improved progression-free survival compared to imlunestrant alone.

Dose rounding within an acceptable range can provide cost savings and minimize waste, but requires careful interprofessional collaboration and patient education.

According to the report, 75% of survey participants expect pharmacists to oversee these therapies and 58% expect Medicare will require pharmacist involvement.

Virginia Kaklamani, MD, DSc, shares the role of ESR1 mutation testing and combination strategies to optimize endocrine therapy in patients with metastatic HR+/HER2- breast cancer.

Experts discuss advancements in hormone receptor–positive/HER2-negative breast cancer treatment while addressing safety, diversity, and fertility challenges.

Navtemadlin has demonstrated meaningful efficacy and safety as a monotherapy or combination treatment in various preclinical and clinical trials.

Results suggest that patients commonly receive more than 5 days of treatment, which could be an opportunity for an antimicrobial stewardship initiative.

Pharmacists are essential members of the patient care team, leveraging technology like automated IV compounding to standardize processes.

The progress made in areas like scope expansion and reimbursement is encouraging, suggesting a growing recognition of pharmacists’ value within the health care system.

Two studies found a 2-bag regimen of N-acetylcysteine (NAC) resulted in fewer and shorter delays in treatment as well as decreases in cutaneous non-allergic anaphylactoid reactions.

Pharmacists play a crucial role in promoting the appropriate use of broad-spectrum antibiotics to prevent antimicrobial resistance and improve patient outcomes.